Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Lutz

Showing results (61-70 of 119) with videos related to

Pageof 12
Sort By:
Zeitschrift Fur Gastroenterologie|February 13, 2019
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis CStefan Mauss, Lukas Buendgens, Stefan Christensen, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2007
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenNils von Hentig, Axel Müller, Carsten Rottmann, et al.
Physiology & Behavior|April 26, 2011
Ghrelin-induced hypothermia: a physiological basis but no clinical riskPetra Wiedmer, Florian Strasser, Tamas L Horvath, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 2, 2017
Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS studyHeiner Wedemeyer, Jens Reimer, Petra Sandow, et al.
Antiviral Therapy|October 13, 2005
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovirJulie Sheldon, Nuria Camino, Berta Rodés, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trialsFrank Tacke, Rainer Günther, Peter Buggisch, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 30, 2010
Deletion of the Chd6 exon 12 affects motor coordinationMelissa J Lathrop, Lisa Chakrabarti, Jeremiah Eng, et al.
Antiviral Therapy|September 30, 2016
Effect of antiviral therapy for HCV on lipid levelsStefan Mauss, Florian Berger, Malte H Wehmeyer, et al.
Virology|August 22, 2015
Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfectionJulia Dietz, Thomas Lutz, Gaby Knecht, et al.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trialJürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, et al.
Pageof 12

Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Zeitschrift Fur Gastroenterologie|February 13, 2019
Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis CStefan Mauss, Lukas Buendgens, Stefan Christensen, et al.
Antimicrobial Agents and Chemotherapy|February 14, 2007
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimenNils von Hentig, Axel Müller, Carsten Rottmann, et al.
Physiology & Behavior|April 26, 2011
Ghrelin-induced hypothermia: a physiological basis but no clinical riskPetra Wiedmer, Florian Strasser, Tamas L Horvath, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 2, 2017
Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS studyHeiner Wedemeyer, Jens Reimer, Petra Sandow, et al.
Antiviral Therapy|October 13, 2005
Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovirJulie Sheldon, Nuria Camino, Berta Rodés, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 19, 2016
Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trialsFrank Tacke, Rainer Günther, Peter Buggisch, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 30, 2010
Deletion of the Chd6 exon 12 affects motor coordinationMelissa J Lathrop, Lisa Chakrabarti, Jeremiah Eng, et al.
Antiviral Therapy|September 30, 2016
Effect of antiviral therapy for HCV on lipid levelsStefan Mauss, Florian Berger, Malte H Wehmeyer, et al.
Virology|August 22, 2015
Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfectionJulia Dietz, Thomas Lutz, Gaby Knecht, et al.
The Lancet. Gastroenterology & Hepatology|April 12, 2017
Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trialJürgen K Rockstroh, Sanjay Bhagani, Robert H Hyland, et al.
Pageof 12